Drug Discovery & DDS– category –
-
Evonik Breaks Ground on Biotechnology Expansion in Slovakia, Strengthening European Pharmaceutical Manufacturing Hub
Evonik Germany Overview On September 14, 2026, Evonik initiated construction for a significant biotechnology manufacturing expansion at its Fermín site in Slovakia. This investment aims to bolster the company's production capacity for ac... -
Lonza to Build New Spray-Drying Facility in Oregon, US, Bolstering CDMO Capabilities in Particle Engineering for Enhanced Bioavailability
SWI swissinfo.ch Switzerland Overview Lonza, a leading Swiss CDMO, announced on September 10, 2026, plans to construct a new state-of-the-art manufacturing facility in Bend, Oregon, specialized in spray-drying technology. Expected to be ... -
Prelude Therapeutics Receives IND Clearance for Oral KAT6A Degrader PRT13722 in HR+/HER2- Breast Cancer Phase 1 Study
MarketBeat USA Overview On September 10, 2026, Prelude Therapeutics announced FDA Investigational New Drug (IND) clearance for PRT13722, an oral KAT6A selective degrader. This compound is being developed for HR-positive/HER2-negative bre... -
FDA Approves Multiple Novel Cancer Therapeutics, Including Multi-Selective RAS(ON) Inhibitor Daraxonrasib and Next-Gen ADCs for Difficult-to-Treat Cancers
The ASCO Post USA Overview The U.S. FDA announced several groundbreaking cancer drug approvals on September 10, 2026, including daraxonrasib, a multi-selective RAS(ON) inhibitor, for metastatic pancreatic adenocarcinoma. Other approvals ... -
Rani Therapeutics Achieves 84% Bioavailability for Oral Ustekinumab Biosimilar; Oral GLP-1s Drive Commercial Success in Biopharma Delivery
Drug Delivery Leader USA Overview The successful FDA approval and commercial launch of oral semaglutide (Wegovy) and orforglipron highlight the critical role of oral delivery in chronic disease management, significantly improving patient... -
OS Therapies Strengthens FDA & MHRA Alignment, Joins Project Orbis for OST-HER2 Metastatic Osteosarcoma Program
OS Therapies USA Overview OS Therapies announced strengthened alignment with the FDA and MHRA and approval to join Project Orbis for its lead candidate, OST-HER2 (a next-generation tunable ADC) program for metastatic osteosarcoma. Projec... -
WuXi XDC Out-Licenses WuXiTecan-2 Linker-Payload Technology to Ona Therapeutics to Accelerate ADC Development
PR Newswire China Overview WuXi XDC announced the out-licensing of its innovative WuXiTecan-2 linker-payload technology platform to Ona Therapeutics, a Spanish biotechnology company, to advance novel Antibody-Drug Conjugate (ADC) researc... -
Nutshell Therapeutics’ NRF2 Molecular Glue Degrader NTS231 Clears FDA IND, Becomes China’s First and World’s Second to Enter Clinical Development
Insight, China's Pharmaceutical Industry China Overview Nutshell Therapeutics' NRF2 molecular glue degrader, NTS231, has cleared FDA IND, becoming the first from China and second globally to enter clinical development as a novel therapeu... -
Shilpa Biologicals Opens GMP Facility for ADC Manufacturing in India’s Pharmacit
Biospectrum Jobs India Overview Shilpa Biologicals has inaugurated a new GMP-compliant facility in Pharmacit, India, dedicated to the manufacturing of Antibody-Drug Conjugates (ADCs). This state-of-the-art facility will provide end-to-en... -
Akeso’s EGFR/TROP2 Bispecific ADC AK158D1 Cleared for Phase I Clinical Trial in Advanced Solid Tumors by China’s NMPA
PR Newswire China Overview Akeso Inc., a Chinese biopharmaceutical company, announced that its EGFR and TROP2 bispecific antibody-drug conjugate (ADC) candidate, AK158D1, has received clearance from China's National Medical Products Admi...
